Selected article for: "antiviral effect and present study"
Author: Al-kuraishy, Hayder M.; Al-Gareeb, Ali I.; Alzahrani, Khalid J.; Alexiou, Athanasios; Batiha, Gaber El-Saber
Title: Niclosamide for Covid-19: bridging the gap
  • Cord-id: wjq5a1bz
  • Document date: 2021_10_18
    • ID: wjq5a1bz
    Snippet: AIM/PURPOSE: Niclosamide (NCL) is an anthelminthic drug, which is widely used to treat various diseases due to its pleiotropic anti-inflammatory and antiviral activities. NCL modulates of uncoupling oxidative phosphorylation and different signaling pathways in human biological processes. The wide-spectrum antiviral effect of NCL makes it a possible candidate for recent pandemic SARS-CoV-2 infection and may reduce Covid-19 severity. Therefore, the aim of the present study was to review and clarif
    Document: AIM/PURPOSE: Niclosamide (NCL) is an anthelminthic drug, which is widely used to treat various diseases due to its pleiotropic anti-inflammatory and antiviral activities. NCL modulates of uncoupling oxidative phosphorylation and different signaling pathways in human biological processes. The wide-spectrum antiviral effect of NCL makes it a possible candidate for recent pandemic SARS-CoV-2 infection and may reduce Covid-19 severity. Therefore, the aim of the present study was to review and clarify the potential role of NCL in Covid-19. METHODS: This study reviewed and highlighted the protective role of NCL therapy in Covid-19. A related literature search in PubMed, Scopus, Web of Science, Google Scholar, and Science Direct was done. RESULTS: NCL has noteworthy anti-inflammatory and antiviral effects. The primary antiviral mechanism of NCL is through neutralization of endosomal PH and inhibition of viral protein maturation. NCL acts as a proton carrier, inhibits homeostasis of endosomal PH, which limiting of viral proliferation and release. The anti-inflammatory effects of NCL are mediated by suppression of inflammatory signaling pathways and release of pro-inflammatory cytokines. However, the major limitation in using NCL is low aqueous solubility, which reduces oral bioavailability and therapeutic serum concentration that reducing the in vivo effect of NCL against SARS-CoV-2. CONCLUSIONS: NCL has anti-inflammatory and immune regulatory effects by modulating the release of pro-inflammatory cytokines, inhibition of NF-κB /NLRP3 inflammasome and mTOR signaling pathway. NCL has an anti-SARS-CoV-2 effect via interruption of viral life-cycle and/or induction of cytopathic effect. Prospective clinical studies and clinical trials are mandatory to confirm the potential role of NCL in patients with Covid-19 concerning the severity and clinical outcomes.

    Search related documents:
    Co phrase search for related documents
    • activation release and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • activation release and acute sars infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • activation release and lung alveolar: 1, 2
    • activation release and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • activation release and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • activation release and macrophage activation syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • activation release and macrophage function: 1
    • activator transcription and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6
    • activator transcription and acute lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • activator transcription and acute sars infection: 1, 2, 3, 4
    • activator transcription and lung alveolar: 1
    • activator transcription and lung alveolar cell: 1
    • activator transcription and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • activator transcription and macrophage activation: 1, 2
    • activator transcription and macrophage activation syndrome: 1
    • acute ards respiratory distress syndrome and long term effect: 1
    • acute ards respiratory distress syndrome and low concentration: 1
    • acute ards respiratory distress syndrome and lung alveolar: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung alveolar cell: 1, 2, 3, 4, 5, 6, 7